Literature DB >> 10352197

Prognosis of parathyroid function after successful percutaneous ethanol injection therapy guided by color Doppler flow mapping in chronic dialysis patients.

T Kakuta1, M Fukagawa, T Fujisaki, M Hida, H Suzuki, H Sakai, K Kurokawa, A Saito.   

Abstract

Selective percutaneous ethanol injection therapy (PEIT) of the parathyroid glands has been shown to be effective in chronic dialysis patients with severe secondary hyperparathyroidism. In this study, we examined whether it was possible to maintain parathyroid function within target range (intact parathyroid hormone [iPTH], 160 to 360 pg/mL) in the long term after successful destruction of hyperplastic tissue. PEIT was performed in 46 patients resistant to calcitriol pulse therapy, and all glands larger than 5 mm in diameter were destroyed by ethanol, guided by power Doppler flow mapping. Serum iPTH levels decreased from 633.3 +/- 359.9 to 226.3 +/- 204.7 pg/mL at 3 weeks and were maintained at 289.9 +/- 222.4 pg/mL at 1 year after PEIT. Total alkaline phosphatase activity decreased from 384.9 +/- 160.1 to 234.0 +/- 110.5 IU/L at 1 year after PEIT. In 19 patients, iPTH levels decreased into relative hypoparathyroidism (iPTH < 160 pg/mL) at 3 weeks after PEIT; however, they recovered at 1 year after PEIT (191.1 +/- 29.6 pg/mL). Parathyroid function was maintained within target range in 80.4% of the patients at 1 year after PEIT with appropriate medical therapy. Surgical parathyroidectomy was not required in any patient. Conversely, in eight other patients with recurrent hyperparathyroidism after subtotal parathyroidectomy, iPTH levels recovered in only 50% of the patients at 1 year after PEIT. Thus, destruction of hyperplastic tissue should be optimized in such patients. Recurrent nerve palsy was observed in only one patient, but was reversible. In conclusion, selective PEIT guided by color Doppler flow mapping is an effective and safe adjunct to medical therapy with a low risk for hypoparathyroidism.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10352197     DOI: 10.1016/S0272-6386(99)70146-0

Source DB:  PubMed          Journal:  Am J Kidney Dis        ISSN: 0272-6386            Impact factor:   8.860


  11 in total

Review 1.  The kidney and bone metabolism: Nephrologists' point of view.

Authors:  Masafumi Fukagawa; Yasuhiro Hamada; Shohei Nakanishi; Motoko Tanaka
Journal:  J Bone Miner Metab       Date:  2006       Impact factor: 2.626

Review 2.  Surgical and medical treatment of secondary hyperparathyroidism in patients on continuous dialysis.

Authors:  Yoshihiro Tominaga; Susumu Matsuoka; Nobuaki Uno
Journal:  World J Surg       Date:  2009-11       Impact factor: 3.352

Review 3.  Secondary hyperparathyroidism in children with chronic renal failure: pathogenesis and treatment.

Authors:  Cheryl P Sanchez
Journal:  Paediatr Drugs       Date:  2003       Impact factor: 3.022

4.  Prevention and treatment of renal osteodystrophy in children on chronic renal failure: European guidelines.

Authors:  G Klaus; A Watson; A Edefonti; M Fischbach; K Rönnholm; F Schaefer; E Simkova; C J Stefanidis; V Strazdins; J Vande Walle; C Schröder; A Zurowska; M Ekim
Journal:  Pediatr Nephrol       Date:  2005-10-25       Impact factor: 3.714

5.  Indication and efficacy of PEIT in the management of secondary hyperparathyroidism.

Authors:  Fumihiko Koiwa; Takeshi Hasegawa; Reika Tanaka; Takatoshi Kakuta
Journal:  NDT Plus       Date:  2008-08

6.  Percutaneous ethanol injection therapy for advanced renal hyperparathyroidism in Japan: 2004 survey by the Japanese Society for Parathyroid Intervention.

Authors:  Takatoshi Kakuta; Masafumi Fukagawa; Masafumi Kitaoka; Fumihiko Koiwa; Noritaka Onoda; Yasuhiro Tominaga; Tadao Akizawa; Kiyoshi Kurokawa
Journal:  NDT Plus       Date:  2008-08

7.  Long-term prognosis of parathyroid function in chronic dialysis patients after PEIT-a single-centre trial.

Authors:  Reika Tanaka; Takatoshi Kakuta; Fumihiko Koiwa; Masafumi Fukagawa; Akira Saito
Journal:  NDT Plus       Date:  2008-08

8.  New clinical guidelines for selective direct injection therapy of the parathyroid glands in chronic dialysis patients.

Authors:  Noritaka Onoda; Masafumi Fukagawa; Yoshihiro Tominaga; Masafumi Kitaoka; Tadao Akizawa; Fumihiko Koiwa; Takatoshi Kakuta; Kiyoshi Kurokawa
Journal:  NDT Plus       Date:  2008-08

9.  Effects of percutaneous ethanol injection therapy on subsequent surgical parathyroidectomy.

Authors:  Michio Nakamura; Yuji Marui; Yoshifumi Ubara; Shohei Nakanishi; Fumi Takemoto; Kenmei Takaichi; Shinji Tomikawa
Journal:  NDT Plus       Date:  2008-08

10.  Medical management after parathyroid intervention.

Authors:  Motoko Tanaka; Masafumi Fukagawa
Journal:  NDT Plus       Date:  2008-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.